Narimatsu A, Nakao K, Ikoma H, Egawa M, Kitada Y, Yamazaki S, Umezu K, Miyake M, Nishimura E, Hashimoto N
Nihon Yakurigaku Zasshi. 1986 Feb;87(2):223-51. doi: 10.1254/fpj.87.223.
MCI-2016 at 3 mg/kg, i.v., caused slight changes in systemic blood pressure (SBP), heart rate (HR), respiratory rate (RR) and ECG but at 10 mg/kg, i.v., it caused a significant increase in RR, decrease in SBP, increase or decrease in HR and a moderate change in ECG. Biphasic changes in SBP, HR and blood flow were sometimes observed after high doses. MCI-2016 also decreased SBP at 30 mg/kg, i.p., in SHR. MCI-2016 (50 mg/kg, p.o./day) showed little influence on SBP, HR and ECG in conscious beagle dogs. In isolated hearts, MCI-2016 decreased HR and contractility at the concentrations above 10(-5) g/ml, and 30 micrograms, i.a. MCI-2016 prolonged the AVCT at 10 mg/kg, i.v. MCI-2016 (i.v. or i.a.) moderately increased cerebral and femoral artery blood flows. MCI-2016 did not change CMRO2, but decreased MVO2. Coronary and renal artery flows were moderately increased by 10 mg/kg, i.v., of MCI-2016. Renal function was suppressed after 10 mg/kg, i.v., or 300 mg/kg, p.o., of MCI-2016. MCI-2016 potentiated the action of NE (increase in SBP, contractions of nictitating membrane and vas deferens), but showed little anti-cholinergic action. In contrast, MCI-2016 moderately increased gastrointestinal motility and salivatory response. As for the influence on isolated smooth muscles, MCI-2016 antagonized the contraction of blood vessels by high K+ at 10(-6) g/ml, or more, and it depressed the contractions by ACh, 5-HT, histamine and BaCl2 and also depressed spontaneous movements of uterus and ileum at 10(-5) M or more, in a nonspecific manner. MCI-2016 had no influence on liver damage and bile secretion, but inhibited stress ulcer and gastric acid secretion on the one hand, and caused gastric damage (125 mg/kg p.o., or more) on the other hand.
静脉注射3mg/kg的MCI - 2016会引起全身血压(SBP)、心率(HR)、呼吸频率(RR)和心电图的轻微变化,但静脉注射10mg/kg时,会导致RR显著增加、SBP降低、HR升高或降低以及心电图出现中度变化。高剂量给药后,有时会观察到SBP、HR和血流的双相变化。腹腔注射30mg/kg的MCI - 2016也会使自发性高血压大鼠(SHR)的SBP降低。口服(每天50mg/kg)的MCI - 2016对清醒的比格犬的SBP、HR和心电图影响较小。在离体心脏中,浓度高于10(-5)g/ml时,MCI - 2016会降低HR和收缩力,心室内注射30μg时也会出现这种情况。静脉注射10mg/kg的MCI - 2016会延长房室传导时间(AVCT)。静脉注射或心室内注射MCI - 2016会适度增加脑动脉和股动脉血流量。MCI - 2016不会改变脑代谢率(CMRO2),但会降低心肌耗氧量(MVO2)。静脉注射10mg/kg的MCI - 2016会适度增加冠状动脉和肾动脉血流量。静脉注射10mg/kg或口服300mg/kg的MCI - 2016后,肾功能会受到抑制。MCI - 2016增强了去甲肾上腺素(NE)的作用(SBP升高、瞬膜和输精管收缩),但抗胆碱作用较弱。相反,MCI - 2016会适度增加胃肠蠕动和唾液分泌反应。至于对离体平滑肌的影响,MCI - 2016在浓度为10(-6)g/ml或更高时可拮抗高钾引起的血管收缩,并且以非特异性方式抑制乙酰胆碱(ACh)、5 - 羟色胺(5 - HT)、组胺和氯化钡(BaCl2)引起的收缩,还会在浓度为10(-5)M或更高时抑制子宫和回肠的自发运动。MCI - 2016对肝损伤和胆汁分泌没有影响,但一方面抑制应激性溃疡和胃酸分泌,另一方面会导致胃损伤(口服125mg/kg或更高剂量)。